Overview

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Status:
Active, not recruiting

Trial end date:
2021-12-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.

Phase:

Phase 1

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Bendamustine Hydrochloride
Rituximab